# Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

> **NCT02238522** · PHASE1 · WITHDRAWN · sponsor: **Zenith Epigenetics**

## Conditions studied

- Lymphoproliferative Malignancies
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ZEN003365

## Key facts

- **NCT ID:** NCT02238522
- **Lead sponsor:** Zenith Epigenetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02238522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02238522, "Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02238522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*